{"name":"Veracyte","slug":"veracyte","ticker":"VCYT","exchange":"NASDAQ","domain":"veracyte.com","description":"Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.","hq":"South San Francisco, CA","founded":0,"employees":"755","ceo":"Marc Stapley","sector":"Genomic Diagnostics","stockPrice":39.01,"stockChange":0.76,"stockChangePercent":1.99,"marketCap":"$3.1B","metrics":{"revenue":541742976,"revenueGrowth":21.5,"grossMargin":72.9,"rdSpend":70814000,"netIncome":66353000,"cash":439060000,"dividendYield":0,"peRatio":36.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Veracyte Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Veracyte reported fourth quarter and full year 2023 financial results, with revenue of $73.4 million and a net loss of $24.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Veracyte Announces Collaboration with AstraZeneca to Develop Companion Diagnostic for Lynparza","summary":"Veracyte announced a collaboration with AstraZeneca to develop a companion diagnostic for Lynparza, a PARP inhibitor used to treat certain types of cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Veracyte Receives FDA Clearance for Envisia Genomic Classifier","summary":"Veracyte received FDA clearance for its Envisia Genomic Classifier, a non-invasive test for diagnosing idiopathic pulmonary fibrosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOS3E5VGUxb19nMUdxZkc2MFdkU1k4QVV3bHFBN0NORFBlYzRmT3hCTGw0S1Z3ZDZQTDRFN0Q2VlR3ZGRfRUhHejNFcEFNUl90WEI5TVhEVEJ5eGsyU3lkTU9LY05KREJuOWdrczVIN21nUHozUS1rQU9jMVhlOTN2MFRDM3VLUDZ6emFLM0dlTjQwR0hQeGZSRDlkUzdxSWIwaXhvbEhHbFJIMTZWcWdEc1JNcmNReUdTN3c?oc=5","date":"2026-03-30","type":"earnings","source":"MSN","summary":"Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound? - MSN","headline":"Veracyte (VCYT) down 15.4% since last earnings report: Can it rebound?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE1Idnk5VVlkbzJtbWlycHdzb0QxQUVkWVNEMnhNRGhWbGg2RVhtZVowN1hGdk5tbG1mWVREZV9hRFZ4UmdyYi1YV0NXQnNsU1hOQW1rYkpMYnJvWmRoUUHSAWNBVV95cUxPWW04TjB0cnA5aDllMWRjQTBhSWxGSVFGa3RMQ2MybjBncEJrUmVpTWtBRHRlRi1rN0FsNjYwWFotWi1rN1I1SE1POWZkYi1XaVFBNU5VMVVZYmgxWnlPSDFDX00?oc=5","date":"2026-03-29","type":"pipeline","source":"Bitget","summary":"Veracyte Drops 8.84% Despite Solid Fundamentals, Technical Indicators Signal Caution - Bitget","headline":"Veracyte Drops 8.84% Despite Solid Fundamentals, Technical Indicators Signal Caution","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-25","type":"pipeline","source":"simplywall.st","summary":"Veracyte Taps Kevin Haas To Guide AI Push And Undervalued Shares - simplywall.st","headline":"Veracyte Taps Kevin Haas To Guide AI Push And Undervalued Shares","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-17","type":"pipeline","source":"simplywall.st","summary":"How Veracyte’s New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story - simplywall.st","headline":"How Veracyte’s New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOaGttS3VhVkdkdjRMQ2J0LWtHc2VuaEJyajEzN2tyaVJXcGRrU3JYb181VlZ4ejVCMFI1bTVpQTJBazN6YWFnbV9nQzh3RkUxYWRiWnROaDAzamQ0ajgtTlVNUjdHNW5aajVSMTBQR184X3FDdWJzX1dYejVXOHFTZ2loNGZVdkM0T0l2WWxoXy04YWNsaFdsNGZIMVpmck4tajZOU2xFZDVuTzctajctbnFqa1hPVG8?oc=5","date":"2026-03-16","type":"pipeline","source":"Stock Titan","summary":"Ex-Myriad Genetics tech chief joins cancer test maker Veracyte - Stock Titan","headline":"Ex-Myriad Genetics tech chief joins cancer test maker Veracyte","sentiment":"neutral"},{"date":"2026-03-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-03","type":"pipeline","source":"simplywall.st","summary":"Veracyte (VCYT) Valuation Check After Mixed Short And Long Term Share Price Performance - simplywall.st","headline":"Veracyte (VCYT) Valuation Check After Mixed Short And Long Term Share Price Performance","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-25","type":"pipeline","source":"simplywall.st","summary":"Is Veracyte (VCYT) Pricing Reflect Its Genomic Diagnostics Role After Recent Share Price Weakness - simplywall.st","headline":"Is Veracyte (VCYT) Pricing Reflect Its Genomic Diagnostics Role After Recent Share Price Weakness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPVUhmeHpFVi13VmUtR1pqbW0zYlRlV1d1WXJvZEpQSzI4TVRyQUtSMDdYMVkycUFRMHNob19panBfUmRtU3JTdUVpazhMMFhTdThWMmtsTV9IdlpCMVVldDdNSUhZdXdYOXZqUzhPLUNGOTl4c3BIb2hCSnRwQkJPUTMwOVVyc0JHXzZqUXF5ZVhnSzJnRnlRcWFWUTVwcHFLdmU1THJrNnozay00TGVPYUJfYXg0emw1M2pCSHoycUFHUEdCT1E?oc=5","date":"2026-02-25","type":"earnings","source":"Business Wire","summary":"Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results - Business Wire","headline":"Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPc3JDbFJPODI5UXVSanptcnpfM3N4azMzbGdsekpIUmpmc2hPYWFWOUhPMUc0dW9DS2xFR2FjcXJMR3d1WWJ1NHJhSWxnTDdBQXVXcERmLW9WcE5MWmQ1RWdfZC0zNURsbGNJUm1CMWY2TnRaX0VwUlN5TUw2djJWWXRVVXJZYk9TT2RuRGhGUlg?oc=5","date":"2026-01-16","type":"earnings","source":"Seeking Alpha","summary":"Veracyte: Profitable, De-Risked, And Ready To Run (NASDAQ:VCYT) - Seeking Alpha","headline":"Veracyte: Profitable, De-Risked, And Ready To Run (NASDAQ:VCYT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1jSUdDSG51ZnVUdnltalRBTE5YVEw2MHF5dU4taWNnMnFFREp2c3hQSlZXZGVkRFNtRU1MV01CSjNGb2R3MEJBaEUya3piR25BRTJud2l1bkJ4ZlRfWG5VTVJvb0lKdTNx?oc=5","date":"2025-08-28","type":"regulatory","source":"MarketBeat","summary":"Veracyte (VCYT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VCYT - MarketBeat","headline":"Veracyte (VCYT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VCYT","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOeFVpZ25MeTBiOVVEZDFzNEkyRTJ0dlpibnZOejAzbVBkMWhLdHZTb0huMVh5RjkwZ3dOaVFaNHlMNzY5bGJmUE9pR09Tei1ZMGRjSkZHZFd2Z0k2cE14NlNqRTlhRk1pM201a3V3RlhzeXRTTzByc1pSNURTQXBFQWhuWW1RV1N5aEZHWmduR05BdkFoZjNEWkVubmxQRVVJd2tBSkM3VkNObU9R?oc=5","date":"2024-12-12","type":"pipeline","source":"Investor's Business Daily","summary":"Why This Stock, With A 55% Run, Is An Outlier In Diagnostics - Investor's Business Daily","headline":"Why This Stock, With A 55% Run, Is An Outlier In Diagnostics - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE9pQklQYVZXdVpZWlZlb3dKbFJwblNYdzhZdmJEYjVFUXMwbUdsMVdqdHFTTVlDOE1sWTBiRUkwbDFkTWJkV20zT09QM3dDWFBm?oc=5","date":"2021-09-14","type":"pipeline","source":"The Motley Fool","summary":"Veracyte - VCYT - Stock Price & News - The Motley Fool","headline":"Veracyte - VCYT - Stock Price & News","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Exact Sciences","Foundation Medicine","Invitae"],"therapeuticFocus":["Cancer Diagnostics"],"financials":{"source":"sec_edgar+yahoo","revenue":517145000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":517145000,"period":"2025-12-31"},{"value":445764000,"period":"2024-12-31"},{"value":445764000,"period":"2024-12-31"},{"value":361051000,"period":"2023-12-31"},{"value":361051000,"period":"2023-12-31"}],"grossProfit":362532000,"grossProfitHistory":[{"period":"2025-12-31","value":362532000},{"period":"2024-12-31","value":298145000},{"period":"2023-12-31","value":229684000},{"period":"2022-12-31","value":175681000}],"rdSpend":70814000,"rdSpendHistory":[{"period":"2025-12-31","value":70814000},{"period":"2024-12-31","value":69294000},{"period":"2023-12-31","value":57305000},{"period":"2022-12-31","value":40603000}],"sgaSpend":210949000,"operatingIncome":78282000,"operatingIncomeHistory":[{"period":"2025-12-31","value":78282000},{"period":"2024-12-31","value":19510000},{"period":"2023-12-31","value":-17446000},{"period":"2022-12-31","value":-35340000}],"netIncome":66353000,"netIncomeHistory":[{"period":"2025-12-31","value":66353000},{"period":"2024-12-31","value":24138000},{"period":"2023-12-31","value":-74404000},{"period":"2022-12-31","value":-36560000}],"eps":0.82,"epsHistory":[{"period":"2025-12-31","value":0.82},{"period":"2024-12-31","value":0.31},{"period":"2023-12-31","value":-1.02},{"period":"2022-12-31","value":-0.51}],"cash":362578000,"cashHistory":[{"period":"2025-12-31","value":362578000},{"period":"2024-12-31","value":239087000},{"period":"2023-12-31","value":216454000},{"period":"2022-12-31","value":154247000}],"totalAssets":1406019000,"totalLiabilities":96443000,"totalDebt":39654000,"equity":1309576000,"operatingCashflow":136307000,"operatingCashflowHistory":[{"period":"2025-12-31","value":136307000},{"period":"2024-12-31","value":75096000},{"period":"2023-12-31","value":44222000},{"period":"2022-12-31","value":7535000}],"capex":-9677000,"capexHistory":[{"period":"2025-12-31","value":-9677000},{"period":"2024-12-31","value":-11287000},{"period":"2023-12-31","value":-9961000},{"period":"2022-12-31","value":-8549000}],"freeCashflow":126630000,"dividendsPaid":null,"buybacks":null,"employees":755,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":43470000,"ebit":40634000,"ebitda":45932000,"period":"2025-12-31","revenue":140636000,"epsBasic":0.52,"netIncome":41149000,"rdExpense":20849000,"epsDiluted":0.51,"grossProfit":101973000,"operatingIncome":39908000},{"sga":50706000,"ebit":18889000,"ebitda":24155000,"period":"2025-09-30","revenue":131872000,"epsBasic":0.24,"netIncome":19137000,"rdExpense":15981000,"epsDiluted":0.24,"grossProfit":91282000,"operatingIncome":23112000},{"sga":57612000,"ebit":1250000,"ebitda":6739000,"period":"2025-06-30","revenue":130164000,"epsBasic":-0.01,"netIncome":-980000,"rdExpense":16264000,"epsDiluted":-0.01,"grossProfit":89769000,"operatingIncome":14312000},{"sga":59161000,"ebit":1164000,"ebitda":6526000,"period":"2025-03-31","revenue":114473000,"epsBasic":0.09,"netIncome":7047000,"rdExpense":17720000,"epsDiluted":0.09,"grossProfit":79508000,"operatingIncome":1164000},{"sga":54807000,"ebit":3443000,"ebitda":9696000,"period":"2024-12-31","revenue":118632000,"epsBasic":0.07,"netIncome":5113000,"rdExpense":19290000,"epsDiluted":0.06,"grossProfit":78754000,"operatingIncome":6034000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":39.01,"previousClose":38.25,"fiftyTwoWeekHigh":50.71,"fiftyTwoWeekLow":22.61,"fiftyTwoWeekRange":"22.61 - 50.71","fiftyDayAverage":33.74,"twoHundredDayAverage":36.09,"beta":1.89,"enterpriseValue":2652341760,"forwardPE":20.5,"priceToBook":2.36,"priceToSales":5.74,"enterpriseToRevenue":4.9,"enterpriseToEbitda":25.45,"pegRatio":0,"ebitda":104212000,"ebitdaMargin":19.2,"freeCashflow":104506000,"operatingCashflow":166160000,"totalDebt":39333000,"debtToEquity":2.9,"currentRatio":9.3,"returnOnAssets":3.8,"returnOnEquity":6.9,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":10,"targetMeanPrice":47.4,"targetHighPrice":55,"targetLowPrice":37,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.5,"institutionHeldPercent":109.5,"sharesOutstanding":79792647,"floatShares":79351394,"sharesShort":6870870,"shortRatio":9.27,"shortPercentOfFloat":8.6,"epsTrailing":1.08,"epsForward":1.91,"revenuePerShare":6.86,"bookValue":16.5,"officers":[{"age":55,"name":"Mr. Marc A. Stapley","title":"CEO & Director"},{"age":47,"name":"Ms. Rebecca  Chambers","title":"Executive VP & CFO"},{"age":59,"name":"Dr. Phillip G. Febbo M.D.","title":"Chief Scientific & Medical Officer"},{"age":44,"name":"Ms. Annie  McGuire","title":"Executive VP, General Counsel & Head of Market Access"},{"age":53,"name":"Dr. John  Leite Ph.D.","title":"Global Chief Commercial Officer"},{"age":null,"name":"Dr. Keith  Gligorich Ph.D.","title":"Senior Vice President of Global Operations"},{"age":54,"name":"Mr. Jonathan  Wygant","title":"VP & Chief Accounting Officer"},{"age":40,"name":"Dr. Kevin Richard Haas Ph.D.","title":"Chief Development and Technology Officer"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.veracyte.com","phone":"650 243 6300"}}